Empirical studies have established that corporate intangibles assets such as Research and Development (R&D), employee satisfaction, firm reputation and celebrity status, are valued by market participants. R&D expenditures lead to higher future profitability and stock market investors price them positively. These investments do not appear to be superior since the average stock returns of R&D and non‐R&D firms are comparable. However, portfolios of high R&D intensity and of large unexpected increases in R&D earn positive future abnormal returns. This has sparked an ongoing debate as to whether the abnormal returns represent investor mispricing or compensation for risk. Since R&D spending is treated as a period expense in the financial reports, the potential mispricing has also been attributed to the limited disclosures and accounting practiced. Financial analysts appear to play an important role in compensating for R&D‐related financial reporting deficiencies but the compensation is far from complete. Successful R&D activity leads to patents which have also been shown to be positively associated with stock market values and future earnings. However, results show that neither analysts nor investors appear to fully understand the implications of patent information. Overall, there is a need for continued effort by policy makers to address intangibles‐related information deficiencies.